Leonteq Securities AG Has $111,000 Stake in Intellia Therapeutics, Inc. $NTLA

Leonteq Securities AG lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 84.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,666 shares of the company’s stock after selling 48,124 shares during the period. Leonteq Securities AG’s holdings in Intellia Therapeutics were worth $111,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of NTLA. ARK Investment Management LLC boosted its stake in shares of Intellia Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after purchasing an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after buying an additional 1,965,181 shares during the period. State Street Corp raised its holdings in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after buying an additional 1,447,967 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Intellia Therapeutics by 2.7% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock worth $47,435,000 after buying an additional 71,000 shares during the period. Finally, Geode Capital Management LLC boosted its position in Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after buying an additional 107,333 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Down 2.3%

NTLA opened at $17.43 on Wednesday. Intellia Therapeutics, Inc. has a twelve month low of $7.95 and a twelve month high of $28.25. The company has a fifty day moving average of $14.25 and a 200-day moving average of $13.19. The stock has a market cap of $2.44 billion, a PE ratio of -4.92 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the previous year, the business earned ($1.10) earnings per share. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -3.18 EPS for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. New Street Research set a $25.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Wall Street Zen lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Chardan Capital increased their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, April 27th. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, The Goldman Sachs Group lifted their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $20.46.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.